Drug
Sage 718
Sage 718: highest development phase Phase 3, developed by Supernus Pharmaceuticals. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Supernus Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAGE-718 NCT05655520 | Phase 3 | Huntington's Disease |
| SAGE-718 NCT05358821 | Phase 2 | Huntington Disease |
| SAGE-718 NCT05318937 | Phase 2 | Parkinson Disease |
| SAGE-718 NCT05107128 | Phase 2 | Huntington's Disease |
| SAGE-718 NCT03771586 | Phase 1 | Healthy Volunteer |
| SAGE-718 NCT03844906 | Phase 1 | Healthy Volunteer |
Latest
No recent events.
Follow Sage 718 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.